These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

604 related articles for article (PubMed ID: 33637650)

  • 1. Discovery and characterization of bromodomain 2-specific inhibitors of BRDT.
    Yu Z; Ku AF; Anglin JL; Sharma R; Ucisik MN; Faver JC; Li F; Nyshadham P; Simmons N; Sharma KL; Nagarajan S; Riehle K; Kaur G; Sankaran B; Storl-Desmond M; Palmer SS; Young DW; Kim C; Matzuk MM
    Proc Natl Acad Sci U S A; 2021 Mar; 118(9):. PubMed ID: 33637650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of potent BET bromodomain 1 stereoselective inhibitors using DNA-encoded chemical library selections.
    Modukuri RK; Yu Z; Tan Z; Ta HM; Ucisik MN; Jin Z; Anglin JL; Sharma KL; Nyshadham P; Li F; Riehle K; Faver JC; Duong K; Nagarajan S; Simmons N; Palmer SS; Teng M; Young DW; Yi JS; Kim C; Matzuk MM
    Proc Natl Acad Sci U S A; 2022 May; 119(22):e2122506119. PubMed ID: 35622893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of
    Sheppard GS; Wang L; Fidanze SD; Hasvold LA; Liu D; Pratt JK; Park CH; Longenecker K; Qiu W; Torrent M; Kovar PJ; Bui M; Faivre E; Huang X; Lin X; Wilcox D; Zhang L; Shen Y; Albert DH; Magoc TJ; Rajaraman G; Kati WM; McDaniel KF
    J Med Chem; 2020 May; 63(10):5585-5623. PubMed ID: 32324999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dihydropyridine Lactam Analogs Targeting BET Bromodomains.
    Jiang J; Sigua LH; Chan A; Kalra P; Pomerantz WCK; Schönbrunn E; Qi J; Georg GI
    ChemMedChem; 2022 Jan; 17(1):e202100407. PubMed ID: 34932262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer.
    Faivre EJ; McDaniel KF; Albert DH; Mantena SR; Plotnik JP; Wilcox D; Zhang L; Bui MH; Sheppard GS; Wang L; Sehgal V; Lin X; Huang X; Lu X; Uziel T; Hessler P; Lam LT; Bellin RJ; Mehta G; Fidanze S; Pratt JK; Liu D; Hasvold LA; Sun C; Panchal SC; Nicolette JJ; Fossey SL; Park CH; Longenecker K; Bigelow L; Torrent M; Rosenberg SH; Kati WM; Shen Y
    Nature; 2020 Feb; 578(7794):306-310. PubMed ID: 31969702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Affinity map of bromodomain protein 4 (BRD4) interactions with the histone H4 tail and the small molecule inhibitor JQ1.
    Jung M; Philpott M; Müller S; Schulze J; Badock V; Eberspächer U; Moosmayer D; Bader B; Schmees N; Fernández-Montalván A; Haendler B
    J Biol Chem; 2014 Mar; 289(13):9304-19. PubMed ID: 24497639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective inhibition mechanism of RVX-208 to the second bromodomain of bromo and extraterminal proteins: insight from microsecond molecular dynamics simulations.
    Wang Q; Li Y; Xu J; Wang Y; Leung EL; Liu L; Yao X
    Sci Rep; 2017 Aug; 7(1):8857. PubMed ID: 28821780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Computational study on the selective inhibition mechanism of MS402 to the first and second bromodomains of BRD4.
    Wang Q; Li Y; Xu J; Wang Y; Shi D; Liu L; Leung EL; Yao X
    Proteins; 2019 Jan; 87(1):3-11. PubMed ID: 30260047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of Tetrahydroquinoxalines as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the Second Bromodomain.
    Law RP; Atkinson SJ; Bamborough P; Chung CW; Demont EH; Gordon LJ; Lindon M; Prinjha RK; Watson AJB; Hirst DJ
    J Med Chem; 2018 May; 61(10):4317-4334. PubMed ID: 29656650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The binding mechanism of NHWD-870 to bromodomain-containing protein 4 based on molecular dynamics simulations and free energy calculation.
    Shi M; He J; Weng T; Shi N; Qi W; Guo Y; Chen T; Chen L; Xu D
    Phys Chem Chem Phys; 2022 Feb; 24(8):5125-5137. PubMed ID: 35156677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small-molecule inhibition of BRDT for male contraception.
    Matzuk MM; McKeown MR; Filippakopoulos P; Li Q; Ma L; Agno JE; Lemieux ME; Picaud S; Yu RN; Qi J; Knapp S; Bradner JE
    Cell; 2012 Aug; 150(4):673-84. PubMed ID: 22901802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of ZA channel water-mediated interactions in the design of bromodomain-selective BET inhibitors.
    Bharatham N; Slavish PJ; Shadrick WR; Young BM; Shelat AA
    J Mol Graph Model; 2018 May; 81():197-210. PubMed ID: 29605436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-Based Design of a Bromodomain and Extraterminal Domain (BET) Inhibitor Selective for the N-Terminal Bromodomains That Retains an Anti-inflammatory and Antiproliferative Phenotype.
    Wellaway CR; Bamborough P; Bernard SG; Chung CW; Craggs PD; Cutler L; Demont EH; Evans JP; Gordon L; Karamshi B; Lewis AJ; Lindon MJ; Mitchell DJ; Rioja I; Soden PE; Taylor S; Watson RJ; Willis R; Woolven JM; Wyspiańska BS; Kerr WJ; Prinjha RK
    J Med Chem; 2020 Sep; 63(17):9020-9044. PubMed ID: 32787145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Covalent-Fragment Screening of BRD4 Identifies a Ligandable Site Orthogonal to the Acetyl-Lysine Binding Sites.
    Olp MD; Sprague DJ; Goetz CJ; Kathman SG; Wynia-Smith SL; Shishodia S; Summers SB; Xu Z; Statsyuk AV; Smith BC
    ACS Chem Biol; 2020 Apr; 15(4):1036-1049. PubMed ID: 32149490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interactome Rewiring Following Pharmacological Targeting of BET Bromodomains.
    Lambert JP; Picaud S; Fujisawa T; Hou H; Savitsky P; Uusküla-Reimand L; Gupta GD; Abdouni H; Lin ZY; Tucholska M; Knight JDR; Gonzalez-Badillo B; St-Denis N; Newman JA; Stucki M; Pelletier L; Bandeira N; Wilson MD; Filippakopoulos P; Gingras AC
    Mol Cell; 2019 Feb; 73(3):621-638.e17. PubMed ID: 30554943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Binding pocket-based design, synthesis and biological evaluation of novel selective BRD4-BD1 inhibitors.
    Ma J; Chen H; Yang J; Yu Z; Huang P; Yang H; Zheng B; Liu R; Li Q; Hu G; Chen Z
    Bioorg Med Chem; 2019 May; 27(9):1871-1881. PubMed ID: 30926312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A theoretical insight into selectivity of inhibitors toward two domains of bromodomain-containing protein 4 using molecular dynamics simulations.
    Su J; Liu X; Zhang S; Yan F; Zhang Q; Chen J
    Chem Biol Drug Des; 2018 Mar; 91(3):828-840. PubMed ID: 29139214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. When are the BET factors the most sensitive to bromodomain inhibitors?
    Khochbin S
    Transcription; 2013; 4(2):54-7. PubMed ID: 23412362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of Benzo[d]imidazole-6-sulfonamides as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the First Bromodomain.
    Cipriano A; Milite C; Feoli A; Viviano M; Pepe G; Campiglia P; Sarno G; Picaud S; Imaide S; Makukhin N; Filippakopoulos P; Ciulli A; Castellano S; Sbardella G
    ChemMedChem; 2022 Oct; 17(20):e202200343. PubMed ID: 36040095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and Characterization of a Positron Emission Tomography Imaging Probe Selectively Targeting the Second Bromodomain of Bromodomain Protein BRD4.
    Bai P; Lan Y; Wang H; Liu Y; Striar R; Yuan G; Afshar S; Zagaroli JS; Tocci DR; Langan AG; Wang C
    Bioconjug Chem; 2021 Aug; 32(8):1711-1718. PubMed ID: 34139120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.